Inactive Instrument

Christian Hansen

CHR

DK0060227585

Chr. Hansen Holding A/S Reports Earnings Results for the First Quarter Ended November 30, 2019

January 15, 2020 at 03:46 am

Chr. Hansen Holding A/S announced earnings results for the first quarter ended November 30, 2019. For the first quarter, the company announced sales was EUR 272.4 million compared to EUR 269.4 million a year ago. Net income was EUR 49.9 million compared to EUR 51.1 million a year ago. Basic earnings per share was EUR 0.38 compared to EUR 0.39 a year ago.

Latest news about Christian Hansen

Novozymes, Chr. Hansen Complete Merger Settlement	02-02	MT
Chr. Hansen Holding A/S(CPSE:CHR) dropped from OMX Nordic All-Share Index	02-01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from FTSE All-World Index	02-01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P EUROPE 350 - Materials	02-01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P EUROPE 350	02-01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P EUROPE 350 - Materials (Industry Group)	02-01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P International 700	02-01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P Global 1200	02-01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P Global BMI Index	02-01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from OMX Copenhagen 20 Index	01-30	CI
Novozymes Completes Merger with Chr. Hansen After Securing Final Registration, Issuing B Shares	01-29	MT
Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S.	01-28	CI
Novozymes, Chr. Hansen’s Proposed Merger Secures All Regulatory Approvals	01-26	MT
Nordic Stocks Decreased Wednesday; Kone B Posted Biggest Loss	01-17	DJ
Novozymes, Chr. Hansen Merger Wins Korean Regulatory Nod	12-20	MT
Novozymes-Chr. Hansen Merger Gets EU Nod After Proposed Asset Sale	12-12	MT
Kerry Group Buys Novozymes, Chr. Hansen Assets for EUR150 Million	12-12	DJ
European Commission clears Novozymes, Chr. Hansen merger	12-12	RE
Kerry Group plc agreed to acquire Lactase enzyme business from Chr. Hansen Holding A/S and Novozymes A/S (CPSE:NZYM B) for ?150 million.	12-11	CI
Simon Barnard: A long-term vision at Smithson	12-07
EU regulators likely to clear Novozymes, Chr. Hansen deal, sources say	12-06	RE
EU ANTITRUST REGULATORS LIKELY TO APPROVE NOVOZYMES, C…	12-06	RE
EU Competition Watchdog Extends Novozymes, Chr. Hansen Merger Decision	11-21	MT
EU extends decision date on Novoyzmes, Chr. Hansen deal to Dec. 12	11-21	RE
Novozymes, Chr. Hansen Propose Remedy to Secure EU Approval for Merger	11-20	MT

Chart Christian Hansen

Duration

Period

More charts

Company Profile

Chr. Hansen Holding A/S specializes in the development, production and marketing of biotechnological ingredients for the food processing, animal feed and health industries. Net sales (excluding activities being sold) break down by family of products as follows: - cultivations and enzymes (62.6%); - medical and nutritional ingredients (37.4%): used in the manufacturing of dietary supplements, OTC drugs, baby products and animal feed. Net sales are distributed geographically as follows: Denmark (0.8%), Europe/Middle East/Africa (36.4%), the United States (30.3%), North America (2.4%), Asia/Pacific (18.7%) and Latin America (11.4%).

Sector

Food Processing

Calendar

2024-08-14 - Q2 2024 Earnings Release

More about the company

Sector Food Ingredients

	1st Jan change	Capi.
FOSHAN HAITIAN FLAVOURING AND FOOD COMPANY LTD.	-7.51%	26.85B
INTERNATIONAL FLAVORS & FRAGRANCES INC.	+19.50%	24.71B
KIKKOMAN CORPORATION	+14.34%	11.67B
LANCASTER COLONY CORPORATION	+14.80%	5.26B
MEIHUA HOLDINGS GROUP CO.,LTD	+8.80%	4.08B
ANGEL YEAST CO., LTD	-17.06%	3.45B
KEWPIE CORPORATION	+54.56%	3.36B
TATE & LYLE PLC	-1.82%	3.22B
JONJEE HI-TECH INDUSTRIAL AND COMMERCIAL HOLDING CO.,LTD	-30.14%	2.07B

Food Ingredients